How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,789 results for

Allergic Conjunctivitis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Seasonal Allergic Conjunctivitis (Hay Fever Conjunctivitis); Perennial Allergic Conjunctivitis

Seasonal Allergic Conjunctivitis (Hay Fever Conjunctivitis); Perennial Allergic Conjunctivitis Seasonal Allergic Conjunctivitis (Hay Fever Conjunctivitis); Perennial Allergic Conjunctivitis submit The College submit You're here: Seasonal Allergic Conjunctivitis (Hay Fever Conjunctivitis); Perennial Allergic Conjunctivitis Seasonal Allergic Conjunctivitis (Hay Fever Conjunctivitis); Perennial Allergic Conjunctivitis The CMGs are guidelines on the diagnosis and management of a range of common (...) and rare, but important, eye conditions that present with varying frequency in primary and first contact care. Share options Aetiology Type I hypersensitivity reaction to specific airborne allergens Conjunctival mast cell degranulation liberates histamine and other inflammatory mediators into the tissues and tear film, causing dilatation of conjunctival vessels (red eye), increased permeability of blood vessels (oedema), itch Seasonal allergic conjunctivitis (hay fever conjunctivitis) (SAC) caused

2018 College of Optometrists

3. Conjunctivitis (Acute Allergic)

Conjunctivitis (Acute Allergic) Conjunctivitis (Acute Allergic) submit The College submit You're here: Conjunctivitis (Acute Allergic) Conjunctivitis (Acute Allergic) The CMGs are guidelines on the diagnosis and management of a range of common and rare, but important, eye conditions that present with varying frequency in primary and first contact care. Share options Aetiology A self-limiting urticarial reaction to an allergen (often unidentified) that comes into contact with the conjunctiva (...) allergic conjunctivitis Chemical trauma Preseptal or orbital cellulitis Management by optometrist Practitioners should recognise their limitations and where necessary seek further advice or refer the patient elsewhere GRADE* Level of evidence and strength of recommendation always relates to the statement(s) immediately above Non pharmacological Reassure patient: most cases resolve spontaneously within a few hours Advise against eye rubbing (causes mechanical mast cell degranulation) Cool compresses may

2018 College of Optometrists

4. Olopatadine for the Treatment of Allergic Conjunctivitis: A Review of the Clinical Efficacy, Safety, and Cost-Effectiveness

Olopatadine for the Treatment of Allergic Conjunctivitis: A Review of the Clinical Efficacy, Safety, and Cost-Effectiveness Olopatadine for the Treatment of Allergic Conjunctivitis: A Review of the Clinical Efficacy, Safety, and Cost-Effectiveness | CADTH.ca Find the information you need Olopatadine for the Treatment of Allergic Conjunctivitis: A Review of the Clinical Efficacy, Safety, and Cost-Effectiveness Olopatadine for the Treatment of Allergic Conjunctivitis: A Review of the Clinical (...) Efficacy, Safety, and Cost-Effectiveness Published on: March 17, 2016 Project Number: RC0756-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question 1. What is the clinical efficacy and safety of olopatadine for the treatment of allergic conjunctivitis? 2. What is the cost-effectiveness of olopatadine for the treatment of allergic conjunctivitis? Key Message Pooled estimates from four studies included in a systematic review showed

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

5. Cromolyn for Allergic Conjunctivitis: Clinical Effectiveness

Cromolyn for Allergic Conjunctivitis: Clinical Effectiveness Cromolyn for Allergic Conjunctivitis: Clinical Effectiveness | CADTH.ca Find the information you need Cromolyn for Allergic Conjunctivitis: Clinical Effectiveness Cromolyn for Allergic Conjunctivitis: Clinical Effectiveness Published on: January 29, 2016 Project Number: RA0830-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical effectiveness and safety of cromolyn sodium (...) for the treatment of allergic conjunctivitis? Key Message One systematic review was identified regarding the clinical effectiveness of cromolyn sodium for allergic conjunctivitis. Tags conjunctivitis, cromolyn sodium, eye, Allergic Files Rapid Response Reference List Published : January 29, 2016 Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

6. Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis. (PubMed)

Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis. Seasonal/perennial allergic conjunctivitis is the most common allergic conjunctivitis, usually with acute manifestations when a person is exposed to allergens and with typical signs and symptoms including itching, redness, and tearing. The clinical signs and symptoms of allergic conjunctivitis are mediated by the release of histamine by mast cells. Histamine antagonists (also called (...) searches for trials. We last searched the electronic databases on 17 July 2014. We also searched the reference lists of review articles and relevant trial reports for details of further relevant publications.We included randomised controlled trials (RCTs) comparing topical antihistamine and mast cell stabilisers, alone or in combination, with placebo, no treatment or to any other antihistamine or mast cell stabiliser, or both, that examined people with seasonal or perennial allergic conjunctivitis

Full Text available with Trip Pro

2015 Cochrane

7. The effectiveness of olopatadine hydrochloride eye drops for allergic conjunctivitis: protocol for a systematic review

The effectiveness of olopatadine hydrochloride eye drops for allergic conjunctivitis: protocol for a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

8. Evaluating the efficacy of epinastine ophthalmic solution using a conjunctivitis allergen challenge model in patients with birch pollen allergic conjunctivitis. (PubMed)

Evaluating the efficacy of epinastine ophthalmic solution using a conjunctivitis allergen challenge model in patients with birch pollen allergic conjunctivitis. The efficacy of epinastine 0.05% ophthalmic solution for pollen allergic conjunctivitis has already been shown in a conjunctival allergen challenge (CAC) test using cedar pollen as a challenge. The present study investigated the efficacy of this solution against birch pollen conjunctivitis in a CAC test.Ten adult subjects (eight males (...) and two females) with asymptomatic birch pollen conjunctivitis were enrolled in this study. The average age of the subjects was 41.1 years. This study was conducted during a period without birch pollen dispersion. In each subject, the epinastine 0.05% ophthalmic solution was instilled in one eye, and an artificial tear fluid was instilled in the fellow eye in a double-blind manner. Five minutes or 4 h after the drug instillation, both eyes were challenged with an optimal concentration of birch pollen

Full Text available with Trip Pro

2017 Allergology international : official journal of the Japanese Society of Allergology

9. CL-associated Papillary Conjunctivitis (CLAPC), Giant Papillary Conjunctivitis (GPC)

with fluorescein when inflammation active apices may be whitish due to scarring in chronic cases hyperaemia stringy mucus in tear film and on conjunctival surfaces conjunctival oedema Differential diagnosis Vernal Keratoconjunctivitis, Atopic Keratoconjunctivitis, Seasonal Allergic Conjunctivitis, Superior Limbic Keratoconjunctivitis contact lens history will aid diagnosis Distinguish papillae from follicles: Follicles: hyperplasia of lymphoid tissue generally seen in viral or chlamydial conditions smooth (...) CL-associated Papillary Conjunctivitis (CLAPC), Giant Papillary Conjunctivitis (GPC) CL-associated Papillary Conjunctivitis (CLAPC), Giant Papillary Conjunctivitis (GPC) submit The College submit You're here: CL-associated Papillary Conjunctivitis (CLAPC), Giant Papillary Conjunctivitis (GPC) CL-associated Papillary Conjunctivitis (CLAPC), Giant Papillary Conjunctivitis (GPC) The CMGs are guidelines on the diagnosis and management of a range of common and rare, but important, eye conditions

2018 College of Optometrists

10. Diagnosing and managing allergic conjunctivitis in childhood: the allergist's perspective. (PubMed)

Diagnosing and managing allergic conjunctivitis in childhood: the allergist's perspective. Allergic conjunctivitis (AC) in childhood often poses problems of diagnosis and management for the allergist. We present the salient points concerning the diagnosis and treatment of ocular allergy (OA) emerging from a large cohort survey conducted jointly in the departments of ophthalmology and paediatric allergy in a French teaching hospital. Seasonal acute conjunctivitis (SAC) is a common disorder (...) and not overly difficult to diagnose and treat when associated with rhinitis leading to allergic rhinoconjunctivitis. An ophthalmologist should be consulted when conjunctivitis occurs alone and if another form of conjunctivitis is suspected, such as perennial allergic conjunctivitis (PAC), vernal keratoconjunctivitis (VKC) or atopic keratoconjunctivitis (AKC). When IgE-mediated hypersensitivity assessment does not establish aetiological diagnosis a conjunctival allergen provocation test (CAPT) can

2019 Pediatric Allergy and Immunology

11. Self-Reported Allergic Rhinitis and/or Allergic Conjunctivitis Associate with IL13 rs20541 Polymorphism in Finnish Adult Asthma Patients. (PubMed)

Self-Reported Allergic Rhinitis and/or Allergic Conjunctivitis Associate with IL13 rs20541 Polymorphism in Finnish Adult Asthma Patients. Our aim was to observe factors associated with IL13 rs20541 polymorphism and other factors with or without allergic comorbidities such as subject-reported allergic rhinitis (AR) and/or allergic conjunctivitis (AC) symptoms in adult asthmatics.A population-based sample of Finnish adult asthma patients (n = 1,156) and matched controls (n = 1,792) filled

2017 International Archives of Allergy and Immunology

12. Model for Studying Anti- Allergic Drugs for Allergic Conjunctivitis in Animals (PubMed)

Model for Studying Anti- Allergic Drugs for Allergic Conjunctivitis in Animals Allergic conjunctivitis (AC), which is characterized by ocular itching, hyperemia, and edema, deteriorates quality of life. In this study, effects of anti-allergic drugs were evaluated by assessing eye-scratching behavior, the number of eosinophils in conjunctiva epithelial tissues, and concentrations of chemical mediators in the tears of the guinea pig model of ovalbumin (OA)-induced AC.On day 0, 3-week-old guinea (...) pigs were sensitized by OA subconjunctival injections. On days 15, 17, and 19, OA solution was administered. Anti-allergic eye drops were administered 5 and 15 min before the final OA challenge on day 19. Scratching behavior within 1 h after OA exposure was studied. Eosinophils in the conjunctiva were stained with Giemsa reagent. Histamine and substance P (SP) concentrations in tears were measured using ELISA.Subconjunctivally injected guinea pigs were observed for clinical symptoms. Scratching

Full Text available with Trip Pro

2017 Open Medicine

13. Correction: Effects of Exposure to Ozone on the Ocular Surface in an Experimental Model of Allergic Conjunctivitis. (PubMed)

Correction: Effects of Exposure to Ozone on the Ocular Surface in an Experimental Model of Allergic Conjunctivitis. [This corrects the article DOI: 10.1371/journal.pone.0169209.].

Full Text available with Trip Pro

2017 PLoS ONE

14. Effects of Exposure to Ozone on the Ocular Surface in an Experimental Model of Allergic Conjunctivitis. (PubMed)

Effects of Exposure to Ozone on the Ocular Surface in an Experimental Model of Allergic Conjunctivitis. Based on previous findings that ozone can induce an inflammatory response in the ocular surface of an animal model and in cultured human conjunctival epithelial cells, we investigated whether exposure to ozone exacerbates symptoms of allergic conjunctivitis. We evaluated the effects of exposure to ozone on conjunctival chemosis, conjunctival injection, corneal and conjunctival fluorescein (...) staining scores, production of inflammatory cytokines in tears, and aqueous tear production in a mouse model of allergic conjunctivitis. To validate our in vivo results, we used interleukin (IL)-1α-pretreated conjunctival epithelial cells as an in vitro substitute for the mouse model. We evaluated whether exposure to ozone increased the inflammatory response and altered oxidative status and mitochondrial function in IL-1α-pretreated conjunctival epithelial cells. In the in vivo study, ozone induced

Full Text available with Trip Pro

2017 PLoS ONE

15. Alcaftadine 0.25% versus Olopatadine 0.1% in Preventing Cedar Pollen Allergic Conjunctivitis in Japan: A Randomized Study. (PubMed)

Alcaftadine 0.25% versus Olopatadine 0.1% in Preventing Cedar Pollen Allergic Conjunctivitis in Japan: A Randomized Study. To compare alcaftadine and olopatadine ophthalmic solutions, and vehicle for preventing allergen-mediated conjunctivitis in Japanese subjects.Japanese cedar pollen-sensitive subjects were randomized to alcaftadine 0.25%, olopatadine 0.1%, or vehicle. Ocular itching was assessed at 3, 5 (primary outcome), 7, and 15 min post-conjunctival allergen challenge (CAC (...) ). Alcaftadine and olopatadine were well tolerated; no serious adverse events were reported.Alcaftadine 0.25% is effective in preventing signs and symptoms of Japanese cedar pollen-induced allergic conjunctivitis.

Full Text available with Trip Pro

2018 Ocular immunology and inflammation

16. IL-27 Signaling Deficiency Develops Th17-enhanced Th2-dominant Inflammation in Murine Allergic Conjunctivitis Model. (PubMed)

IL-27 Signaling Deficiency Develops Th17-enhanced Th2-dominant Inflammation in Murine Allergic Conjunctivitis Model. While most studies focus on pro-allergic cytokines, the protective role of immunosuppressive cytokines in allergic inflammation is not well elucidated. This study was to explore a novel anti-inflammatory role and cellular/molecular mechanism of IL-27 in allergic inflammation.A murine model of experimental allergic conjunctivitis (EAC) was induced in BALB/c, C57BL/6 or IL-27Rα (...) -deficient (WSX-1-/- ) mice by short ragweed pollen, with untreated or PBS-treated mice as controls. The serum, eyeballs, conjunctiva, cervical lymph nodes (CLNs) were used for study. Gene expression was determined by RT-qPCR, and protein production and activation were evaluated by immunostaining, ELISA and Western blotting.Typical allergic manifestations and stimulated thymic stromal lymphopoietin (TSLP) signaling and Th2 responses were observed in ocular surface of EAC models in BALB/c and C57BL/6 mice

2018 Allergy

17. A Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber

A Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber A Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. A Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details

2018 Clinical Trials

18. A Biodegradable, Sustained-Released, Tacrolimus Microfilm Drug Delivery System for the Management of Allergic Conjunctivitis in a Mouse Model. (PubMed)

A Biodegradable, Sustained-Released, Tacrolimus Microfilm Drug Delivery System for the Management of Allergic Conjunctivitis in a Mouse Model. To investigate the drug release profiles of a tacrolimus-loaded poly(D,L-lactide-co-ε-caprolactone) (PLC) microfilm, and to evaluate its efficacy on the treatment of allergic conjunctivitis using a mouse model.The in vitro and in vivo drug release profiles were first characterized. Balb/c mice were immunized with short ragweed (SRW) injection followed (...) by re-challenges with topical SRW solution. The mice were divided into six groups (n = 12 in each): negative control (NC); positive control (PC); tacrolimus eye drops (Te); subconjunctival tacrolimus microfilm (Tm); dexamethasone eye drops (De); and tacrolimus + dexamethasone eye drops (Te+De). The mice were evaluated for 28 days by a scoring system for allergic conjunctivitis. Histopathologic and immunohistochemical staining with CD11c, CD4, and IL-4 were performed.The microfilms were biocompatible

Full Text available with Trip Pro

2018 Investigative Ophthalmology & Visual Science

19. Allergic Conjunctivitis-induced Retinal Inflammation Promotes Myopia Progression (PubMed)

Allergic Conjunctivitis-induced Retinal Inflammation Promotes Myopia Progression Myopia is a highly prevalent eye disease. There is limited information suggesting a relationship between myopia and inflammation. We found children with allergic conjunctivitis (AC) had the highest adjusted odds ratio (1.75, 95% confidence interval [CI], 1.72-1.77) for myopia among the four allergic diseases. A cohort study was conducted and confirmed that children with AC had a higher incidence and subsequent risk (...) , and IL-8 secreted by retinal pigment epithelial cells. The expression levels of TNF-α, IL-6, IL-8, monocyte chemoattractant protein-1, and nuclear factor kappa B were up-regulated in eyes with AC, whereas IL-10 and the inhibitor of kappa B were down-regulated. In conclusion, the experimental findings in mice corroborate the epidemiological data showing that allergic inflammation influences the development of myopia.Copyright © 2018. Published by Elsevier B.V.

Full Text available with Trip Pro

2018 EBioMedicine

20. A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis

A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>